FDA Approvals, In Brief: Novartis’ Meningitis Vaccine Bexsero Gets Early Nod
This article was originally published in The Pink Sheet Daily
Executive Summary
Also, Rockwell’s iron deficiency treatment Triferic gains agency approval, but without a dose-sparing claim related to erythropoiesis-stimulating agents; Symplmed’s perindopril/amlodipine fixed-dose combination approved for hypertension.
You may also be interested in...
Keeping Track: DMD, RMAT, HIV, BTDs, Tc-99m – FTW
The latest drug development news and highlights from our US FDA Performance Tracker.
Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market
Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.